Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL509431 | 0.91 | TLR7 (0.72) | TLR7NUDT1 | |
| SCHEMBL7205519 | 0.91 | TLR7 (0.65) | TLR7 | |
| SCHEMBL7205436 | 0.90 | TLR7 (0.61) | TLR7 | |
| SCHEMBL4128956 | 0.90 | TLR7 (0.61) | TLR7NUDT1 | |
| SCHEMBL22533653 | 0.90 | TLR7 (0.61) | TLR7NUDT1 | |
| SCHEMBL21449093 | 0.90 | TLR7 (0.61) | TLR7NUDT1 | |
| SCHEMBL7210381 | 0.90 | TLR7 (0.73) | TLR7 | |
| SCHEMBL7204280 | 0.90 | TLR7 (0.61) | TLR7 | |
| SCHEMBL7211538 | 0.89 | TLR7 (0.60) | TLR7NUDT1 | |
| SCHEMBL12726879 | 0.89 | TLR7 (0.60) | TLR7NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211863-B2 | Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-8211863-B2 | Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-8211863-B2 | Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-20120028999-A1 | ADMINISTRATION OF TLR7 LIGANDS AND PRODRUGS THEREOF FOR TREATMENT OF INFECTION BY HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120028999-A1 | ADMINISTRATION OF TLR7 LIGANDS AND PRODRUGS THEREOF FOR TREATMENT OF INFECTION BY HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120028999-A1 | ADMINISTRATION OF TLR7 LIGANDS AND PRODRUGS THEREOF FOR TREATMENT OF INFECTION BY HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-8034802-B2 | Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2011-10-11 | — | — | US | disclosed |
| US-8034802-B2 | Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2011-10-11 | — | — | US | disclosed |
| US-8034802-B2 | Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2011-10-11 | — | — | US | disclosed |
| US-7858637-B2 | Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus | AVERETT DEVRON R | 2010-12-28 | — | — | US | disclosed |
| US-20090298863-A1 | ADMINISTRATION OF TLR7 LIGANDS AND PRODRUGS THEREOF FOR TREATMENT OF INFECTION BY HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-7576068-B2 | Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576068-B2 | Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576068-B2 | Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| EP-1667694-A2 | TLR7 LIGANDS FOR THE TREATMENT OF HEPATITIS C | Anadys Pharmaceuticals, Inc. (US) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005025583-A2 | TLR7 LIGANDS FOR THE TREATMENT OF HEPATITIS C | ANADYS PHARMACEUTICALS, INC. (US) | 2005-03-24 | — | — | WO | disclosed |
| US-20050054590-A1 | Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus | ANADYS PHARMACEUTICALS, INC. | 2005-03-10 | — | — | US | disclosed |
| EP-1035123-B1 | NOVEL HETEROCYCLIC COMPOUNDS | SUMITOMO PHARMA (JP) | 2003-08-20 | — | — | EP | disclosed |
| US-6329381-B1 | INTERFERONS, VIRICIDES AND ANTICARCINOGENIC AGENTS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2001-12-11 | — | — | US | disclosed |
| EP-1035123-A1 | NOVEL HETEROCYCLIC COMPOUNDS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2000-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298863-A1 | ADMINISTRATION OF TLR7 LIGANDS AND PRODRUGS THEREOF FOR TREATMENT OF INFECTION BY HEPATITIS C VIRUS | TLR7, TLR3, TLR9 | TLR7 1/4885NUDT1 150/4885 |
| US-20120028999-A1 | ADMINISTRATION OF TLR7 LIGANDS AND PRODRUGS THEREOF FOR TREATMENT OF INFECTION BY HEPATITIS C VIRUS | TLR7, TLR3, TLR9 | TLR7 1/4885NUDT1 150/4885 |
| US-20050054590-A1 | Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus | TLR7, TLR3, TLR9 | TLR7 1/4885NUDT1 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.